反応式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]([NH:11][C:12]2[S:13][C:14]3[CH:20]=[C:19]([C:21](O)=[O:22])[CH:18]=[CH:17][C:15]=3[N:16]=2)=[O:10])=[C:4]([F:24])[CH:3]=1.[NH2:25][C:26]1[CH:35]=[CH:34][C:29]2[NH:30][C:31](=[O:33])[O:32][C:28]=2[CH:27]=1.CCN=C=NCCCN(C)C.Cl.C1C=CC2N(O)N=NC=2C=1>CN(C=O)C>[O:33]=[C:31]1[NH:30][C:29]2[CH:34]=[CH:35][C:26]([NH:25][C:21]([C:19]3[CH:18]=[CH:17][C:15]4[N:16]=[C:12]([NH:11][C:9](=[O:10])[CH2:8][C:5]5[CH:6]=[CH:7][C:2]([Cl:1])=[CH:3][C:4]=5[F:24])[S:13][C:14]=4[CH:20]=3)=[O:22])=[CH:27][C:28]=2[O:32]1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
Starting material 37 (60 mg, 0.2 mmol, 70% content) and 6-Amino-3H-benzooxazol-2-one (30, 25 mg, 0.2 mmol) were dissolved in 2 ml DMF. Then EDCl (38 mg, 0.2 mmol) and HOBt (31 mg, 0.2 mmol) were added. The reaction was stirred over night at ambient temperature, concentrated in vacuo and purified by prep HPLC (Method 1). By concentration of the pure fractions the desired product 38 (23 mg, 0.04 mmol, 24%) could be isolated.
後処理
- concentrationconcentrated in vacuo
- custompurified by prep HPLC (Method 1)
出典と根拠
- ORDレコード
- ord-8d817f441e4c481f9302ba7614b06267
- 出典データセット
- uspto-grants-2013_07
- 特許番号
- US08497283B2
関連ノート
読み込み中…